| Betterchem |
| [2007 Index Page] |
|
|
|
|
Title 21 - Food and Drugs
CHAPTER I - FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED)
PART 201 - LABELING
|
|||
| 201-1 | Drugs; name and place of business of manufacturer, packer, or distributor. | ||
| 201-2 | Drugs and devices; National Drug Code numbers. | ||
| 201-5 | Drugs; adequate directions for use. | ||
| 201-6 | Drugs; misleading statements. | ||
| 201-10 | Drugs; statement of ingredients. | ||
| 201-15 | Drugs; prominence of required label statements. | ||
| 201-16 | Drugs; Spanish-language version of certain required statements. | ||
| 201-17 | Drugs; location of expiration date. | ||
| 201-18 | Drugs; significance of control numbers. | ||
| 201-19 | Drugs; use of term ``infant''. | ||
| 201-20 | Declaration of presence of FD&C Yellow No. 5 and/or FD&C Yellow No. 6 in certain drugs for human use. | ||
| 201-21 | Declaration of presence of phenylalanine as a component of aspartame in over-the-counter and prescription drugs for human use. | ||
| 201-22 | Prescription drugs containing sulfites; required warning statements. | ||
| 201-23 | Required pediatric studies. | ||
| 201-24 | Labeling for systemic antibacterial drug products. | ||
| 201-25 | Bar code label requirements. | ||
| 201-50 | Statement of identity. | ||
| 201-51 | Declaration of net quantity of contents. | ||
| 201-55 | Statement of dosage. | ||
| 201-56 | Requirements on content and format of labeling for human prescription drug and biological products. | ||
| 201-57 | Specific requirements on content and format of labeling for human prescription drug and biological products described in 201-56(b)(1). | ||
| 201-58 | Waiver of labeling requirements. | ||
| 201-60 | Principal display panel. | ||
| 201-61 | Statement of identity. | ||
| 201-62 | Declaration of net quantity of contents. | ||
| 201-63 | Pregnancy/breast-feeding warning. | ||
| 201-64 | Sodium labeling. | ||
| 201-66 | Format and content requirements for over-the-counter (OTC) drug product labeling. | ||
| 201-70 | Calcium labeling. | ||
| 201-71 | Magnesium labeling. | ||
| 201-72 | Potassium labeling. | ||
| 201-100 | Prescription drugs for human use. | ||
| 201-100 | Prescription drugs for human use. | ||
| 201-105 | Veterinary drugs. | ||
| 201-115 | New drugs or new animal drugs. | ||
| 201-116 | Drugs having commonly known directions. | ||
| 201-117 | Inactive ingredients. | ||
| 201-119 | In vitro diagnostic products. | ||
| 201-120 | Prescription chemicals and other prescription components. | ||
| 201-122 | Drugs for processing, repacking, or manufacturing. | ||
| 201-125 | Drugs for use in teaching, law enforcement, research, and analysis. | ||
| 201-127 | Drugs; expiration of exemptions. | ||
| 201-128 | Meaning of ``intended uses''. | ||
| 201-129 | Drugs; exemption for radioactive drugs for research use. | ||
| 201-150 | Drugs; processing, labeling, or repacking. | ||
| 201-161 | Carbon dioxide and certain other gases. | ||
| 201-200 | Disclosure of drug efficacy study evaluations in labeling and advertising. | ||
| 201-300 | Notice to manufacturers, packers, and distributors of glandular preparations. | ||
| 201-301 | Notice to manufacturers, packers, and distributors of estrogenic hormone preparations. | ||
| 201-302 | Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil. | ||
| 201-303 | Labeling of drug preparations containing significant proportions of wintergreen oil. | ||
| 201-304 | Tannic acid and barium enema preparations. | ||
| 201-305 | Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings. | ||
| 201-306 | Potassium salt preparations intended for oral ingestion by man. | ||
| 201-307 | Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale. | ||
| 201-308 | Ipecac syrup; warnings and directions for use for over-the-counter sale. | ||
| 201-309 | Acetophenetidin (phenacetin)-containing preparations; necessary warning statement. | ||
| 201-310 | Phenindione; labeling of drug preparations intended for use by man. | ||
| 201-312 | Magnesium sulfate heptahydrate; label declaration on drug products. | ||
| 201-313 | Estradiol labeling. | ||
| 201-314 | Labeling of drug preparations containing salicylates. | ||
| 201-315 | Over-the-counter drugs for minor sore throats; suggested warning. | ||
| 201-316 | Drugs with thyroid hormone activity for human use; required warning. | ||
| 201-317 | Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning. | ||
| 201-319 | Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions. | ||
| 201-320 | Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances. | ||
| 201-322 | Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required alcohol warning. | ||
| 201-323 | Aluminum in large and small volume parenterals used in total parenteral nutrition. | ||